Patents by Inventor Irving L. Weissman

Irving L. Weissman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods For Manipulating Phagocytosis Mediated By CD47
    Publication number: 20160009814
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: July 14, 2015
    Publication date: January 14, 2016
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Methods For Manipulating Phagocytosis Mediated By CD47
    Publication number: 20160009815
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: July 15, 2015
    Publication date: January 14, 2016
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Methods for Achieving Therapeutically Effective Doses of anti-CD47 Agents
    Publication number: 20160008429
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Application
    Filed: February 26, 2014
    Publication date: January 14, 2016
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • CD47 Targeted Therapies for the Treatment of Infectious Disease
    Publication number: 20150376288
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 31, 2015
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune, Irving L. Weissman
  • Markers of acute myeloid leukemia stem cells
    Patent number: 9193955
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: November 24, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman
  • Depletion of teratoma-forming pluripotent stem cells
    Patent number: 9175079
    Abstract: Compositions and methods are provided for depletion of pluripotent cells. In one embodiment of the invention, methods are provided for depletion of pluripotent cells from a mixed population of differentiated cells and stem cells, to provide a population of cells substantially free of pluripotent stem cells. Monoclonal antibodies useful in depletion and in identification of pluripotent stem cells are also provided.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: November 3, 2015
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Chad Tang, Irving L. Weissman, Micha Drukker
  • Isolation and use of melanoma cancer stem cells
    Patent number: 9151760
    Abstract: A set of markers for melanoma cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression CD271.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 6, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Alexander D. Boiko
  • HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47
    Publication number: 20150183874
    Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Isolation and characterization of progenitor cells from mesothelium
    Patent number: 9045734
    Abstract: Populations enriched for smooth muscle progenitors are obtained by selection on the basis of expression of specific cell surface markers.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: June 2, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Yuval Rinkevich
  • Humanized and chimeric monoclonal antibodies to CD47
    Patent number: 9017675
    Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: April 28, 2015
    Assignee: The Board of Trustees of the Leland Sanford Junior University
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • High Affinity Sirp-Alpha Reagents
    Publication number: 20150071905
    Abstract: High affinity SIRP-? reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRP? reagent, which blocks the physiological binding interaction between SIRP? and its ligand CD47.
    Type: Application
    Filed: January 17, 2013
    Publication date: March 12, 2015
    Inventors: Aaron Michael Ring, Kenan Christopher Garcia, Kipp Andrew Weiskopf, Aron M. Levin, Irving L. Weissman
  • SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS
    Publication number: 20140369924
    Abstract: Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
    Type: Application
    Filed: May 12, 2014
    Publication date: December 18, 2014
    Inventors: Irving L. Weissman, Ravindra Majeti, Arash Ash Alizadeh, Mark P. Chao
  • Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
    Publication number: 20140271683
    Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells.
    Type: Application
    Filed: December 21, 2011
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark P. Chao, Rachel Weissman-Tsukamoto, Siddhartha Jaiswal, Ravindra Majeti, Irving L. Weissman
  • Markers of Acute Myeloid Leukemia Stem Cells
    Publication number: 20140255431
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Application
    Filed: January 24, 2014
    Publication date: September 11, 2014
    Inventors: Ravindra Majeti, Irving L. Weissman
  • Identification and isolation of squamous carcinoma stem cells
    Patent number: 8765390
    Abstract: Squamous carcinoma stem cells (SCSC) are identified. The cells can be prospectively isolated or identified from primary tumor samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and to form unique histological microdomains useful in cancer diagnosis.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: July 1, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Laurie Ailles, Irving L. Weissman, Michael Clarke
  • Synergistic anti-CD47 therapy for hematologic cancers
    Patent number: 8758750
    Abstract: Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: June 24, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Ravindra Majeti, Arash Ash Alizadeh, Mark P. Chao
  • Methods for Manipulating Phagocytosis Mediated by CD47
    Publication number: 20140161805
    Abstract: Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
    Type: Application
    Filed: November 1, 2013
    Publication date: June 12, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Catriona Helen M. Jamieson, Irving L. Weissman, Siddhartha Jaiswal, Ravindra Majeti
  • Methods of Treating Acute Myeloid Leukemia by Blocking CD47
    Publication number: 20140161825
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 12, 2014
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Markers of acute myeloid leukemia stem cells
    Patent number: 8709429
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: April 29, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman
  • Methods of Treating Acute Myeloid Leukemia by Blocking CD47
    Publication number: 20140065169
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: July 12, 2013
    Publication date: March 6, 2014
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao